» Articles » PMID: 11391682

Neuroendocrine Cells in Human Prostate Over-express the Anti-apoptosis Protein Survivin

Overview
Journal Prostate
Date 2001 Jun 8
PMID 11391682
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroendocrine (NE) differentiation may be related to the growth and progression of prostate cancer, especially androgen-insensitive tumors. Recently the over-expression of a new anti-apoptosis protein, survivin, has attracted attention for its potential implication in many human cancers. The fact that NE cells in prostate are bcl-2 negative prompted us to investigate if the prostatic NE cells over-express survivin.

Methods: Double immunohistochemical staining and immunofluorescence of chromogranin A (CgA) and survivin were performed in 57 patients with localized prostate cancer who underwent radical prostatectomy. The terminal deoxynucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end-labeling (TUNEL) method was used for apoptosis detection in three prostate cancer specimens with NE differentiation. The relationship between NE differentiation and clinicopathological characteristics, disease progression as well as patient survival, were analyzed retrospectively.

Results: It was found that NE cells in both benign and malignant prostate tissues over-expressed the anti-apoptosis protein survivin. While apoptosis was detected in non-NE epithelial cells, all NE cells were negative for apoptosis detection. During the period of follow-up, 17 (63%) of 27 patients with NE differentiation had prostate cancer progression, while 12 (40%) of 30 patients without NE differentiation had systemic prostate cancer progression. 10 (37%) of 27 patients with NE differentiation died from prostate cancer during the period of follow up, while 6 (20%) of 30 patients without NE differentiation died from prostate cancer. However, none of these characteristics reached statistical significance, probably because of the small number of cases enrolled.

Conclusions: This study discovers that all the prostatic NE cells express the new anti-apoptosis protein survivin. This provides a strong molecular basis for the hypothesis that NE cells may endure stressful conditions and escape from apoptosis. While our results suggest a trend of NE differentiation with poorer prognosis, the prognosis implication cannot be concluded due to our small sample size.

Citing Articles

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer.

Lee C, Chang Y, Liu C, Hsieh M, Huang L, Chu Y Investig Clin Urol. 2022; 63(5):546-553.

PMID: 36068000 PMC: 9448667. DOI: 10.4111/icu.20210450.


Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.

Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J J Exp Clin Cancer Res. 2022; 41(1):46.

PMID: 35109899 PMC: 8808994. DOI: 10.1186/s13046-022-02255-y.


Neuron-specific enolase has potential value as a biomarker for [F]FDG/[Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholoma M, Maus S EJNMMI Res. 2020; 10(1):52.

PMID: 32449086 PMC: 7246282. DOI: 10.1186/s13550-020-00640-2.


Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.

Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C Nat Commun. 2020; 11(1):1884.

PMID: 32313004 PMC: 7171138. DOI: 10.1038/s41467-020-15426-2.


Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.

Buscheck F, Sulimankhil M, Melling N, Hoflmayer D, Hube-Magg C, Simon R Cancer Med. 2020; 9(4):1409-1418.

PMID: 31893572 PMC: 7013067. DOI: 10.1002/cam4.2773.